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Abstract
Asthma is a chronic inflammatory condition of the lower respiratory tract associated with airway hyperreactivity and mucus
obstruction in which a majority of cases are due to an allergic response to environmental allergens. Glucocorticoids such as
prednisone have been standard treatment for many inflammatory diseases for the past 60 years. However, despite their
effectiveness, long-term treatment is often limited by adverse side effects believed to be caused by glucocorticoid receptor-
mediated gene transcription. This has led to the pursuit of compounds that retain the anti-inflammatory properties yet lack
the adverse side effects associated with traditional glucocorticoids. We have developed a novel series of steroidal analogues
(VBP compounds) that have been previously shown to maintain anti-inflammatory properties such as NFkB-inhibition
without inducing glucocorticoid receptor-mediated gene transcription. This study was undertaken to determine the
effectiveness of the lead compound, VBP15, in a mouse model of allergic lung inflammation. We show that VBP15 is as
effective as the traditional glucocorticoid, prednisolone, at reducing three major hallmarks of lung inflammation—NFkB
activity, leukocyte degranulation, and pro-inflammatory cytokine release from human bronchial epithelial cells obtained
from patients with asthma. Moreover, we found that VBP15 is capable of reducing inflammation of the lung in vivo to an
extent similar to that of prednisone. We found that prednisolone–but not VBP15 shortens the tibia in mice upon a 5 week
treatment regimen suggesting effective dissociation of side effects from efficacy. These findings suggest that VBP15 may
represent a potent and safer alternative to traditional glucocorticoids in the treatment of asthma and other inflammatory
diseases.
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Introduction
Asthma is a chronic multi-factorial disorder characterized by
airway inflammation, hyper-responsiveness and mucus hyperse-
cretion, which reflects remodeling of the airway epithelium and of
the underlying basal lamina [1,2]. Asthma is one of the most
common airway inflammatory disorders and its incidence contin-
ues to increase in the United States [3]. The majority of asthma
cases are mediated by an allergic response to environmental
allergens, which results in degranulation of leukocytes such as
eosinophils and mast cells [4,5,6,7,8,9], bronchoconstriction,
smooth muscle contraction, airway inflammation and mucus
overproduction [10]. In addition, the asthmatic epithelium is
inherently inflammogenic and upon injury (e.g. tobacco smoke,
viral exposure, mechanical wounding) can release pro-inflamma-
tory cytokines in the absence of inflammatory cells
[11,12,13,14,15,16].
Glucocorticoids are among the most prescribed drugs for
therapeutic management of a wide variety of acute and chronic
inflammatory conditions including lupus, myositis, rheumatoid
arthritis, muscular dystrophy, and asthma [17,18,19,20]. Despite
their effectiveness, long-term treatment with glucocorticoids is
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limited by severe side effects including glaucoma, adrenal
insufficiency, osteoporosis, cardiomyopathies, short stature, and
mood or sleep disturbances [21,22,23,24,25]. In children with
persistent asthma, inhaled glucocorticoids reduce growth during
the first few years of therapy and height reduction persists
throughout adulthood [26,27].
The beneficial anti-inflammatory properties of glucocorticoids
are due to multiple mechanisms [28]. Many occur shortly (,30
minutes) after glucocorticoid exposure. For example, glucocorti-
coids can inhibit inflammatory transcription factors such as NFkB
and AP-1 via protein-protein signaling activity, resulting in
decreased production of pro-inflammatory cytokines
[29,30,31,32]. Furthermore, glucocorticoids, acting via a non-
genomic mechanism, can insert into cellular lipid bilayers and
exert a biophysical effect on plasma membranes, affecting their
structure and function, thus promoting membrane stability and
even reducing cellular degranulation [33,34,35]. However, the
most well-described mechanism of glucocorticoid action involves
ligand binding to the cytoplasmic soluble glucocorticoid receptor
(GR) to induce nuclear translocation of the ligand-receptor
complex, which then interacts with glucocorticoid response
elements (GREs) in the promoter regions of target genes, affecting
transcription [36]. An increasing body of literature suggests that
this transcriptional pathway is responsible for many of the adverse
side effects associated with long-term glucocorticoid use
[37,38,39].
Thus, a compound that maintains the beneficial anti-inflam-
matory properties of glucocorticoids but lacks the GRE-mediated
transcriptional capabilities would represent an improved thera-
peutic option for patients suffering from inflammatory diseases.
The potential for such a compound has not been well evaluated
with regard to lung inflammation, although inhaled glucocorti-
coids contribute to systemic side-effects, and there is increasing
concern about their safety for treatment of asthma in infants and
young children [40,41]. Therefore, we evaluated the effectiveness
of VBP15 [42], the newly-identified lead compound selected from
a previously described series of D9,11 glucocorticoid analogues
[43], in a murine model of acute allergic lung inflammation and in
differentiated human bronchial epithelial (HBE) cells obtained
from patients diagnosed with asthma. Additionally, we assessed the
potential of long-term VBP15 treatment to inhibit bone growth in
vivo as a means of evaluating its ability to avoid detrimental
glucocorticoid-related side-effects.
Materials and Methods
Ethics Statement
All animal work was conducted according to relevant national
and international guidelines.
Animals
For in vivo OVA-induced lung inflammation studies, female
BALB/c mice at 6 weeks of age were purchased from Jackson
Laboratories (Bar Harbor, Maine). For bone growth studies,
timed-pregnant outbred CD-1 mice (e19) were purchased from
Charles River Laboratories (Frederick, MD) and the male progeny
were used for the experiment. All studies were reviewed and
approved by the Institutional Animal Care and Use Committees at
The George Washington University Medical Center and Chil-
dren’s National Medical Center.
OVA-induced Model of Acute Allergic Lung Inflammation
The lung inflammation model used in the current studies has
been previously described [44,45]. Briefly, mice were primed via
Figure 1. Structure of VBP15 and schematic of the OVA-induced model of acute allergic lung inflammation. (A) Chemical structures of
prednisone (left panel), prednisolone (mid panel), and VBP15 (right panel). VBP compounds include a delta-9,11 double bond and tail group
modifications. (B) Diagram of OVA-induced mouse model of allergic lung inflammation.
doi:10.1371/journal.pone.0063871.g001
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intraperitoneal (i.p.) injection with 50 mg of ovalbumin (OVA) in
PBS with 100 ml of alum (200 ml total volume per mouse) on day 0.
OVA-primed mice were challenged under light anesthesia
(isoflurane) by intranasal delivery of 100 mg of OVA in PBS on
days 7–10. Mice were sacrificed via CO2 exposure on day 12 for
analysis. For in vivo intervention studies, mice (n = 5) received an
oral dose of 20 mg/kg VBP-15 suspended in cherry syrup (30 ml
total volume) on days 6–11. Additional groups of mice (n = 5)
received 5 mg/kg of prednisone in cherry syrup as a positive
control, or cherry syrup alone as a negative control. Following
sacrifice on day 12, leukocytes were collected from the airways via
bronchoalveolar lavage (BAL). For this procedure, a cannula was
inserted into the trachea and two 1 ml washes of cold PBS were
infused in and out of the airways. BAL fluid from individual mice
was then centrifuged and supernatants were stored at 280uC for
cytokine analysis. Following BAL, whole lungs were perfused via
the right ventricle with 20 ml of cold PBS. For some experiments
the lungs were then removed, chopped, and pushed through a
metal strainer to generate single-cell suspensions. BAL and lung
tissue cells were treated with ammonium chloride lysis buffer to
remove red blood cells. The remaining leukocytes were then
counted and stained for FACS analysis with a combination of PE-
Cy5-anti-mouse CD4 and FITC-anti-mouse CD62L to identify
effector/memory CD4+ cells (CD4+/CD62L2). Populations of
eosinophils were identified using forward scatter/side scatter
distribution, as previously described [44]. For studies addressing
lung histopathology, 1 ml of 10% formalin was infused into the
trachea following lung perfusion, and suture thread was used to tie
off the inflated lungs. Fixed lungs were sent in 70% ethanol to
Histoserv Inc. (Germantown, MD) for processing and staining
with hematoxylin and eosin (H&E) and periodic acid Schiff (PAS).
The frequency of PAS-positive airways was determined in a
blinded manner by separately counting total airways and PAS-
positive airways in each section via bright field microscopy.
NFkB Inhibition Assay
The NFkB inhibition assay was modified from a previously
described protocol [46]. Briefly, A549 epithelial cells (Panomics,
Fremont, CA) stably transfected with a luciferase reporter
construct regulated under NFkB response elements were grown
in 75 mm2 flasks according to the manufacturer’s instructions and
transferred to 96-well plates upon reaching confluency. Once
confluent, cells were serum starved for 48 hours and subsequently
treated for 2 hours with increasing doses of VBP15, prednisolone
(the active form of prednisone), or DMSO in serum-free medium
at 37uC. Following treatment, cells were washed twice with PBS
and exposed to TNF-a (100 ng/ml) for 6 hours in serum-free
medium at 37uC. Cells were then washed once with PBS and lysed
with lysis buffer (Promega Corp, Madison, WI) in order to
measure luciferase activity with the Centro LB 960 luminometer
(Berthold Technologies, GmbH & Co, Bad Wildbad, Germany).
Figure 2. VBP15 reduces leukocyte infiltration in the OVA-induced model of acute allergic lung inflammation. OVA-challenged mice
were either left untreated or treated with oral doses of prednisone, VBP15 (20 mg/kg), or cherry syrup alone daily for 6 days. A group of non-
challenged mice (naı¨ve) was included in order to assess basal inflammatory parameters. Lung tissue and BAL cells underwent FACS analysis to
determine the number of infiltrating eosinophils (A and C) and effector/memory CD4+T cells (B and D). Bar graphs represent mean (6SE) cell
numbers. Percentages indicate percentage reduction compared to vehicle control. *p,0.05; **p,0.01; ***p,.001 compared to syrup group with
n = 5 mice per group.
doi:10.1371/journal.pone.0063871.g002
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Human Bronchial Epithelial Cell Culture
Primary differentiated human bronchial epithelial (HBE) cells
obtained from human asthma patients (n = 3) cultured in 12-well
plates on collagen-coated Transwell membrane inserts at an air-
liquid interface were obtained commercially (#AIR-606-Asthma;
MatTek Corporation, Ashland, MA). Upon arrival, cells were
washed in PBS, placed in proprietary medium provided by the
manufacturer, and cultured for 16 hours at 37uC and 5% CO2
after which medium was replaced with identical medium lacking
epidermal growth factor (EGF) and glucocorticoids. Cells were
maintained under these conditions for an additional 22 hours
before being pulse-treated at the basolateral surface for 2 hours
with VBP-15 (10mM) or vehicle control (DMSO). Following
pulsing, cells were placed in EGF/glucocorticoid-free medium,
and 24 hours later, were pulse-treated again for 2 hours.
Figure 3. VBP15 reduces acute allergic lung inflammation. OVA-challenged mice were either left untreated or treated with oral doses of
prednisone, VBP15 (20 mg/kg), or cherry syrup alone daily for 6 days. A group of non-challenged mice (naı¨ve) was included in order to assess basal
inflammatory parameters. Perfused whole lungs were processed for histological analysis and stained with H&E (A) or PAS (B). Images (106
magnification) represent areas of tissue surrounding bronchioles. Arrows on H&E sections indicate inflammatory foci. Percentage of PAS positive
airways were counted via bright field microscopy (C). Bar graph represents mean (6SE)% PAS positive airways. *p,.05; **p,0.01 compared to the
vehicle control group with n = 5 mice per group. IL-13 (D) and RANTES (E) were measured in BAL fluid by flow cytometric bead array. Bar graphs
represent mean (6SE) cytokine concentration values. *p,.05; **p,0.01 compared to syrup group with n = 5 mice per group.
doi:10.1371/journal.pone.0063871.g003
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Basolateral supernatant was removed and stored at 280uC for
cytokine analysis.
Measurement of Cytokines
BAL fluids from individual mice were concentrated 4-fold using
3-kDa cut-off Centricon columns (Millipore, Billerica, MA).
Cytokines from BAL fluid and HBE supernatants were measured
via cytometric bead assays (EBioscience, San Diego, CA)
according to the manufacturer’s protocol.
RBL-2H3 Degranulation Assay
b-hexosaminidase release was used as an index of degranula-
tion. Initially, RBL-2H3 cells (ATCC, Manassas, VA) were plated
in 24-well tissue culture plates in growth media consisting of
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% FBS, and
1% penicillin-streptomycin. Cells were sensitized overnight with
1 mg/ml of anti-dinitrophenol (DNP) clone SPE-7 (Sigma-Aldrich,
St. Louis, MO) at 37uC in growth media. Following sensitization,
cells were washed with PBS, and Earl’s Balanced Salt Solution
(EBSS) (Invitrogen, Carlsbad, CA)+2.5% BSA was added to each
well. Cells were then treated with VBP-15 (50 mM), prednisolone
(50 mM), or an equal volume of DMSO for 7 minutes at 37uC.
Subsequently, DNP-BSA (Sigma-Aldrich) at a concentration of
10 mg/ml was added to each well, and cells were incubated for an
additional 20 minutes at 37uC. A well of untreated cells was lysed
using 0.05% Triton-X-100 as a means of gauging total b-
hexosamindase content. Supernatants and lysates were added to a
96-well plate (20 ml/well) and b-hexosaminidase substrate, p-
nitrophenyl N-acetyl-beta-D-glucosamine (Sigma-Aldrich) in
0.05 M citrate buffer was added at a concentration of 1 mM in
a volume of 20 ml to each well. EBSS+BSA and lysis buffer were
also included on the plate as blank controls. The 96-well plate was
incubated for 45 minutes at 37uC. Following incubation, 160 ml of
sodium carbonate buffer (0.05 M) was added to each well to stop
the reaction. The absorbance from each well was read at 405 nm
using a microplate reader (Molecular Devices, Sunnyvale, CA). b-
hexosaminidase release percentages were determined using the
following formula: %= (Supernatant–blank)/(Total-blank) X 100.
This assay was conducted in triplicate.
Assessment of in vivo bone growth
Male outbred CD-1 mice (12 days of age) were treated orally
with VBP15, prednisolone, or vehicle control (cherry syrup) daily
for 5 weeks after which mice were sacrificed via CO2 and tibias
were removed. Tibia lengths were measured via electronic caliper,
with n= 10 mice/treatment group.
Statistical Analysis
For most experiments, statistical significance was established
using one-way ANOVA with post-hoc Tukey’s test. For the NFkB
inhibition experiment a one-way ANOVA with Bonferroni’s post-
hoc test was used. For HBE cell cytokine analysis, statistical
significance was established by Student’s T-test. All analyses were
performed using Graphpad Prism software.
Results
VBP15 reduces lung inflammation in a murine model of
allergic lung inflammation
VBP compounds, in contrast to prednisone and prednisolone,
contain a delta 9,11 bond (Figure 1A) that abolishes GRE-
mediated gene transcription [43,47]. In the current studies we
wanted to determine if our lead compound, VBP15, would retain
similar anti-inflammatory efficacy compared to prednisone in the
widely used OVA-induced mouse model of allergic lung inflam-
mation (Figure 1B). After a 6-day oral dosing regimen of VBP15,
we observed a significant reduction similar to that of prednisone in
the number of infiltrating eosinophils (55% reduction compared to
vehicle control) (Figure 2A), as well as, effector/memory CD4+T
cells (55% reduction) (Figure 2B) into the lung tissue of OVA-
exposed and challenged mice. These changes in the lung were also
reflected in the airways as there was a striking decrease in the
presence of eosinophils (58% reduction) and CD4+ cells (52%
reduction) in the BAL fluid (Figure 2C and D). Additionally, lung
tissue sections stained with H&E to assess inflammatory pathology
Figure 4. VBP15 inhibits NFkB activity. A549 cells stably-
transfected with a luciferase NFkB construct were exposed to increasing
concentrations of VBP15 or prednisolone (3, 30, 300, 3000 nM) followed
by TNFa stimulation before measuring luciferase activity. Bar graph
represents mean (6SE) luciferase units. *p,.012 (due to the Bonferroni
adjustment for multiple comparisons) compared to treatment with
vehicle control. Data represents 4 biological replicates with assay
performed in triplicate.
doi:10.1371/journal.pone.0063871.g004
Figure 5. VBP15 reduces leukocyte degranulation. Anti-DNP-
sensitized RBL-2H3 cells were treated with prednisolone (50 mM), VBP-
15 (50 mM), or vehicle control (DMSO) for 7 minutes followed by
addition of DNP to induce degranulation. The reaction was allowed to
proceed for an additional 20 minutes before supernatant was removed
and tested for b-hexosaminidase content. A well of untreated cells was
lysed to gauge total b-hexosamindase content. Release percentage was
determined using a formula described in Materials and Methods. Bar
graph represents mean (6SE) release percentage. **p,0.01 compared
to vehicle control. Data represents 3 biological replicates with assay
performed in triplicate. N.S. = Not statistically significant.
doi:10.1371/journal.pone.0063871.g005
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and PAS to assess for mucus overproduction/hypersecretion
displayed a striking reduction in the presence of inflammatory
foci and PAS-positive airways in VBP15-treated mice compared to
mice treated with control cherry syrup alone (Figure 3A and 3B).
VBP15 treatment induced a reduction in the percentage of PAS-
positive airways that was comparable to that observed in tissue
sections of prednisone-treated mice (Figure 3C). Furthermore,
cytokine analysis of BAL fluid from both prednisone and VBP-
treated mice demonstrated significant decreases in the inflamma-
tory cytokine, IL-13 (50% reduction), and the T-cell chemokine,
RANTES (81% reduction) (Figure 3D and 3E). These findings
indicate that VBP15 is capable of reducing lung inflammation in
vivo with a similar potency to that mediated by traditional
glucocorticoids.
VBP15 reduces NFkB activity
Previous studies have shown that glucocorticoids can inhibit the
activity of the pro-inflammatory transcription factor, NFkB,
through a GRE-independent mechanism [47]. Thus, we deter-
mined whether VBP15 had the capacity to inhibit TNFa-induced
NFkB expression in lung-epithelial cells to a similar extent as
traditional glucocorticoids. To accomplish this, we made use of a
TNF-a induced luciferase NFkB construct stably-transfected into
A549 human lung epithelial cells. Interestingly, after pre-treating
A549 cells with VBP15, we found that it had the capacity to
reduce NFkB activity in a dose-response manner to a similar
extent (56% reduction) to that observed with prednisolone, the
active form of prednisone (Figure 4). Cell viability analysis via
MTT assay revealed no significant differences between treatment
groups (data not shown).
VBP15 reduces leukocyte degranulation
Glucocorticoids have been shown to prevent degranulation of
mast cells in a guinea pig model of allergic lung inflammation via a
non-genomic mechanism possibly involving stabilization of the
plasma membrane [34]. We wondered if VBP15 would likewise
inhibit leukocyte degranulation. We addressed this question using
the RBL-2H3 cell line, which has been extensively used for
studying cellular degranulation. We observed that VBP15
significantly inhibited the release of b-hexosaminidase (51%
reduction), a marker for cell degranulation, to an extent similar
to that mediated by prednisolone (Figure 5). This finding supports
the hypothesis that VBP15 is as effective as a traditional
glucocorticoid at inhibiting cell degranulation, a well-described
mechanism involved in the pathogenesis of allergic lung inflam-
mation.
VBP15 reduces inflammatory cytokine secretion from
human epithelial cells
We next determined if VBP15 had an inhibitory effect on
basolateral cytokine secretion in inflammatory epithelial cells from
human bronchial epithelial cells (HBE) obtained from patients
diagnosed with asthma, as we previously demonstrated with
dexamethasone, a classical glucocorticoid [12]. After two short
pulse treatments with VBP15, the basolateral secretion of TGFB1
and IL-13 from HBE cells was almost completely inhibited (87%
and 100%, respectively) (Figure 6). Since epithelial cells isolated
from asthma patients have been shown to release inflammatory
Figure 6. VBP15 reduces basolateral cytokine secretion from human bronchial epithelial cells obtained from asthmatic patients.
HBE cells from 3 separate human donors were pulse-treated with VBP15 (10 mM) or vehicle control (DMSO). Basolateral surface supernatant was
tested for the presence of TGFb1 (left panel) and IL-13 (right panel) by flow cytometric bead array. Bar graphs represent mean (6SE) concentration
values. **, p,0.01 compared to vehicle control with n = 3 donors. N.D. = Not Detectible (lower limit of detection = 4.5 pg/ml).
doi:10.1371/journal.pone.0063871.g006
Figure 7. VBP15 does not induce tibia length shortening.
Wildtype outbred CD1 mice were treated daily for 5 weeks with VBP15
(30 and 45 mg/kg), prednisolone (10 mg/kg) or vehicle control starting
at 12 days of age. At the end of the treatment, tibias were harvested
and measured. Bar graph represents mean (6SE) tibia length values.
*p,0.05 compared to vehicle control with n = 10 mice/group.
doi:10.1371/journal.pone.0063871.g007
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cytokines in the absence of immune cells, this finding suggests that
VBP15 is effective at targeting non-allergy-related mechanisms as
well.
VBP15 does not affect bone growth in vivo
One major known long term side-effect of glucocorticoids is the
detrimental effect on bone growth. Thus, we determined whether
or not extended VBP15 treatment could result in decreased bone
growth by treating young mice (aged 12 days of age) daily for 5
weeks. We found that, contrary to mice treated with prednisolone,
mice receiving VBP15 did not display significant tibia length
shortening (Figure 7). Interestingly, we observed that doses of
VBP15 four times higher than that of prednisolone did not result
in any shortening of the tibia.
Discussion
Asthma is a chronic inflammatory disease that affects over 300
million people worldwide in which the majority of cases are
associated with an allergic response [48]. For the past 60 years,
glucocorticoids have remained the standard of care for chronic, as
well as acute asthma. Despite their effectiveness, severe side effects
such as osteoporosis, cardiomyopathies, and glaucoma limit long-
term use [21,22,23,24,25,26,27,47,49]. Since these detrimental
effects are attributed to GRE-mediated gene transcription [50], we
developed a series of steroidal analogues (VBP compounds) that
lack the GRE-mediated transcriptional properties of traditional
glucocorticoids but retain similar anti-inflammatory potential [43].
Therefore, we hypothesized that our lead VBP compound, VBP15
[42], when benchmarked against traditional glucocorticoids,
would be just as effective in terms of its ability to reduce acute
allergic lung inflammation in vivo.
Using an acute mouse model of allergic lung inflammation, we
show that VBP15 is as effective as prednisone at reducing
parameters of in vivo inflammation including leukocyte (eosinophils
and CD4+ T cells) infiltration, tissue pathology, and mucus
overproduction. In vitro, VBP15 was able to inhibit NFkB activity
in lung epithelial cells to a similar degree to that seen with
prednisolone (the active form of prednisone). Interestingly, we
observed in vivo that both IL-13 and RANTES, two cytokines
regulated by NFkB [51,52] that also promote respective eosinophil
and CD4+ T cell recruitment, were found to be reduced in the
airways of VBP15 treated mice. Moreover, IL-13 is a known
inducer of goblet cell metaplasia and mucus overproduction
[53,54] which was strikingly decreased in lungs of mice that were
treated with VBP15. A well-documented anti-inflammatory effect
of traditional glucocorticoids is that they inhibit the degranulation
of leukocytes via non-genomic and non-GRE-related mechanisms
[34]. We observed that VBP15 was capable of reducing leukocyte
cell degranulation to a similar degree to that seen with
prednisolone. Since RANTES and IL-13 are two products known
to be released by degranulating leukocytes [55,56] and are
reduced in our in vivo studies, we believe that this is an additional
mechanism whereby VBP15 exerts an anti-inflammatory effect
within the context of acute allergic lung inflammation. It is
important to note that conventional steroids may induce beneficial
anti-inflammatory effects via their ability to cause GRE-mediated
transcription. An example of this includes glucocorticoid-induced
GRE-mediated production of IL-10 [57,58,59], a cytokine which
has been shown to reduce allergic lung inflammation in mice [60].
However, despite lacking the ability to induce GRE-mediated
transcription and potential IL-10 production, VBP15 still has the
capacity to reduce allergic lung inflammation to a degree similar to
that of conventional steroids. Mechanistic studies are currently
underway addressing the effect of VBP15 on GR translocation and
how it may affect a potential GR-NFkB protein interaction.
Furthermore, we are planning on investigating how lung cells
grown in hormone-depleted media respond to VBP15 treatment in
vitro.
A major long term side-effect of glucocorticoids is their
detrimental effect on bone growth, especially in children with
asthma. Our data show that daily treatment of young mice with
VBP15 at doses as high as 45 mg/kg does not inhibit bone growth
of the tibia, in contrast to prednisolone. Doses of 20 mg/kg were
shown to be anti-inflammatory in the OVA-induced mouse model
of lung inflammation used in the current study, which mediates
acute allergic responses. While similar acute responses are seen in
human asthmatic patients during exacerbations, the human
disease is predominantly chronic. Indeed, the acute in vivo model
used in this study has some limitations. For example, in contrast to
the human disease, airway remodeling changes accompanied by
collagen deposition and fibrosis are not observed in this model.
However, these changes are observed in a chronic model of
allergic lung inflammation [61]. Studies to establish the potential
efficacy of VBP compounds using this chronic model are currently
underway. These studies will also enable us to assess in vivo the
absence or presence of additional negative side effects traditionally
seen with long-term use of glucocorticoids in chronic asthma.
The pathogenesis of asthma is complex and heterogeneous.
While allergy and the immune response are known to trigger a
majority of asthma cases [5,6,9], other mechanisms of pathogen-
esis have been described. For example, a recent study demon-
strates that HBE cells of asthmatic patients possess intrinsic
inflammatory properties and have the capacity to release pro-
inflammatory cytokines including IL-13 and TGFb1 from their
basolateral surface without any contribution from immune cells.
Interestingly, exposure of HBE cells to pulse-treatment of
traditional glucocorticoids was able to significantly reduce
basolateral secretion of both IL-13 and TGFb1 [12]. We
demonstrate in the current study that VBP compounds were able
to almost completely eliminate basolateral secretion of IL-13 and
TGFb1 from HBE cells that were obtained from asthma patients,
suggesting that these compounds may inhibit pathogenic mech-
anisms in addition to those associated with allergy. Ongoing work
is currently in progress aimed at further characterizing the
function of these cells in response to VBP15 treatment. A bulk
of the non-steroidal treatment options in the clinic revolves around
targeting the allergic response as a means of treating asthma (e.g.
mast cell stabilizers)[62,63]. Since VBP15 may treat multiple
mechanisms of asthma, and since they potentially lack the adverse
glucocorticoid side effects, we believe that this compound may
represent an efficacious and safer alternative to traditional
glucocorticoids in the treatment of asthma and other inflammatory
diseases.
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